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Background  and  Objective:  Estrogen  Receptor  (ER)  expression  promotes  the
resistance of breast cancer cells to chemotherapeutic agents via mechanism involving
regulation of the B-cell lymphoma 2 (BCL-2) proto-oncogene. Overexpression of BCL-2 is
commonly found in various types of cancers, including breast cancer. The BCL-2 expression
might predict the patient’s response to selected chemotherapies. The aim of this study was
to investigate the association between Estrogen Receptor α (ERα) and BCL-2 mRNA
expression and the clinical response to neoadjuvant chemotherapy in breast cancer.
Materials and Methods: This was a longitudinal study of breast cancer patients who
underwent chemotherapy using a cyclophosphamide-adriamycin-5-FU regimen. Detection
of BCL-2 and ERα mRNA expression in tissue samples was conducted using quantitative
Real-Time Polymerase Chain Reaction (qRT-PCR). Evaluation of the clinical response to
chemotherapy was assessed using Response Evaluation Criteria in Solid Tumor (RECIST).
Statistical analysis was performed using t-test and Pearson correlation methods. Results: The
mean value of BCL-2 mRNA expression in the responsive group was 9.887±2.731. The
mean value of BCL-2 mRNA expression in the non-responsive group was 10.017±2.122. The
mean value of the responsive group was lower than that in the non-responsive group, but
there was no significant correlation between BCL-2 mRNA expression and the clinical
response to chemotherapy with an r-value was 0.378 and a p-value = 0.223 (p>0.05). The
mean value of ERα mRNA expression in the responsive group was 10.144±1.945. The mean
value of ERα mRNA expression in the nonresponsive group was 12.433±0.801. The mean
value of the responsive group was lower than that in the nonresponsive group and there was
a significant difference between the baseline ERα mRNA expression and that of the group
that exhibited a clinical response to chemotherapy with a p-value = 0.006 (p>0.05). There
was a negative correlation between ERα mRNA expression and the clinical response to
chemotherapy  with  an  r-value  =  -0.260,  but  this  correlation  was  insignificant  with  a
p-value = 0.166 (p>0.05). Conclusion: These results suggest that BCL-2 mRNA expression
has a minimal influence in the clinical response of breast cancer to neoadjuvant
chemotherapy, while elevated mRNA expression of ERα has some association with a lack
of responsiveness to neoadjuvant chemotherapy.
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INTRODUCTION
Cancer develops due to disruption of the balance of cell
growth and death1. Tumor cells tend to interfere with this
balance by activating genes that either promote cell growth or
inhibit apoptosis2. The B-cell lymphoma-2 (BCL-2) family
plays a role in the regulation of apoptosis. Disrupted regulation
of apoptosis is a causative event in many diseases. Since
proteins in the BCL-2 family are key regulators of apoptosis,
abnormalities in its function have been implicated in many
diseases3. Tumor resistance to apoptosis is usually caused by
either dysregulation of the expression of BCL-2 family
proteins or mutation of the tumor suppressor gene p532,4.
Overexpression of BCL-2 is commonly found in various types
of cancers, including breast cancer5,6. The BCL-2 is an
important clinical prognostic marker in breast cancer and
patients positive for BCL-2 expression tend to relapse and
have a shorter overall survival7,8. Studies revealed that
analyzing BCL-2 might predict the patient response to selected
endocrine-based and other chemotherapies5-7,9.
Breast cancer is usually a hormone-dependent tumor.
Estrogens can regulate the growth of breast cells by binding to
Estrogen Receptor (ER)10,11. Exposure to estrogen could
increase the incidence and proliferation of breast cancer.
Estrogen receptor also plays a role in the successful treatment
of breast cancer. Estrogen has been implicated in breast cancer
due to its pro-survival effects. The actions of estrogen are
mediated by the estrogen receptor12,13. Estrogen Receptor α
(ERα) is a nuclear receptor that functions as a ligand-activated
transcription factor8. Estrogen E2 enhances cancer cell survival
in part through its ability to upregulate BCL-2 expression. The
ERα has been shown to play an integral role in regulating
BCL-2 expression14. The objective of this study was to
investigate the role of mRNA expression of BCL-2 and ERα
prior initiating chemotherapy as predictor of the
chemotherapeutic response in breast cancer.
MATERIALS AND METHODS
Sample collection: This study was conducted within a
population of breast cancer patients who were clinically and
histopathologically diagnosed with breast cancer and was
treated at the Wahidin Sudiro Husodo Hospital in Makassar,
South Sulawesi, Indonesia.
All the patients who fulfilled the inclusion criteria were
willing to participate in the study and signed informed consent
were  recruited  as  research  subjects.  The  cohort  consisted
of 30 patients with breast cancer who underwent a
chemotherapeutic regimen comprising cyclophosphamide,
adriamycin and 5-FU.
Nucleic acid isolation: Nucleic acid was extracted from breast
cancer tissue using the diatom guanidinium isothiocyanate
(GuSCN) method described by Boom et al15. The tissue
samples were mixed with 500 µL of lysis buffer L6 (50 mM
tris-HCl, 5.25 M GuSCN, 20 mM EDTA, 0.1% Triton X100),
vigorously vortexed and centrifuged at 1,000 rpm for 5 min.
After collecting the nucleic acid, the samples were lysed by
incubating for 15 min at 18°C and 20 µL of diatom suspension
was added. The diatom containing the bound nucleic acid was
centrifuged at 12,000× g for 15 sec to obtain the diatom pellet.
The diatom pellet was then washed with washing buffer L2
(5.25 M GuSCN in 0.1 M tris-HCl, pH 6.4), rinsed with 70%
ethanol and acetone and dried at 56°C for 10 min. The pellet
was  resuspended  in  60  µL  of  buffer  comprising  10  mM
tris-HCl (pH 8.0) and 1 mM EDTA buffer and the nucleic acid
was eluted by incubating the samples at 56°C for 10 min. After
sedimentation of the diatom by centrifugation, the supernatant
was collected and stored at -20°C until real-time PCR was
performed15.
mRNA expression of BCL-2 genes by real-time PCR:
Detection of mRNA expression of BCL-2 was performed
using the real-time PCR method previously described by
Martinez-Arribas3. Specific primers for the BCL-2 mRNA
sequence are listed in Table 13. Each sample was measured in
triplicate.
Expression mRNA ERα by real time PCR: Detection of
ERα mRNA expression was conducted using a real-time PCR.
The following primers to detect ERα mRNA were used:
forward: 5’-TGCTTCAGGCTACCATTATGGAGTCTG-3’
and reverse: 5’-GTCAGGGACAAGGCCAGGCTG-3’. The
reactions were run on a One-Step Quantitative RT-PCR
system according to the manufacturer’s instructions and the
cycling conditions for ERα were as follows: 94°C for 3 min
and 38 cycles of 94°C for 30 sec and 51°C for 30 sec. Each
sample was measured in triplicate16,17.
Data analysis: Data were analyzed using Statistical Package
for Social Science (SPSS) version 22. The normality of the
samples was analyzed using Shapiro-Wilk's test. The patient
characteristics and clinical response were analyzed using the
chi-square test. The mean difference of the BCL-2 mRNA
expression levels between the responsive and non-responsive
groups was assessed using the t-test and correlations were
determined using the Pearson and Spearman tests18.
Ethical clearance: Ethical approval for this study was
obtained from the Research Ethics Committee at the Faculty
of Medicine, Hasanuddin University, Makassar, Indonesia
(Number 1581/H4.8.4.5.31/PP36-KOMETIK/2015, Register
UH15060492).
RESULTS
Samples were collected from 30 individuals with invasive
breast carcinoma between July 2015 and August 2016 who
were examined at Wahidin Sudirohusodo Hospital. The
youngest subject was 28 years old and the oldest was 64 years
old, the mean age of the subjects was 50.3 years (Table 2). The
histopathological grading is summarized in Table 2.
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Table 1: Primer sequences and conditions used3
Primers Sequences (5'-3') Amplicon size (bp) Annealing temperature (°C)
BCl-2a CCCTGTGGATGACTGAGTAC
BCl-2b GCATGTTGACTTCACTTGTG 211 54
AC 1 GACCCAGATCATGTTTGAG
AC 2 GAGTTGAAGGTAGTTTCGTG 486 55
Process Time Temperature (°C)
RT-PCR
Inverse transcription 30 min 50
Activation prior to PCR 15 min 95
PCR
Denaturation 1 min 95
Annealing 30 sec 55
Extension 1 min 72
No. of cycles 34 cycles
Final extension 10 min 72
Table 2: Clinicopathological characteristics of the patients
Characteristics Number Percentage
Age
<50 14 46.7
>50 16 53.3
Grades
Low grade 2 6.7
Moderate grade 19 63.3
High grade 9 30.0
Immunohistochemistrys
ER+ 8 26.7
PR+ 11 36.6
HER2+ 17 56.6
Clinical response
Responsive 23 76.7
Nonresponsive 7 23.3
Comparisons of BCL-2 mRNA expression with clinical
response to neoadjuvant chemotherapy is shown in Table 3.
The mean value of BCL-2 mRNA expression in breast cancer
patients was 9.917±2.568. The mean value of BCL-2 mRNA
expression in the responsive group was 9.887±2.731. The
mean value of BCL-2 mRNA expression in the nonresponsive
group was 10.017±2.122. The mean value of the responsive
group was lower than that in the nonresponsive group as seen
in Fig. 1, but there was no significant difference between the
baseline BCL-2 mRNA expression and the clinical response to
chemotherapy with p-value = 0.862 (p>0.05).
Figure 1 shows the mean value of the responsive group
was lower than that in the nonresponsive.
Comparisons of ERα mRNA expression with clinical
response to neoadjuvant chemotherapy is shown in Table 3.
The mean value of ERα mRNA expression in breast cancer
patients was 10.678±1.993. The mean value of ERα mRNA
expression in the responsive group was 10.144±1.945. The
mean value of ERα mRNA expression in the nonresponsive
group was 12.433±0.801. The mean value of the responsive
group was lower than that in the nonresponsive group as seen
in Fig. 2. There was a significant difference between the
baseline ERα mRNA expression and the clinical response to
chemotherapy with p-value = 0.006 (p>0.05).
Figure 2 shows the mean value of the responsive group
was lower than that in the nonresponsive group.
Fig. 1: Box plot comparing BCL-2 mRNA expression and the
clinical response to chemotherapy
Fig. 2: Box plot comparing ERα mRNA expression and the
clinical response to chemotherapy
Correlation of BCL-2 and ERα mRNA expression with
the clinical response to chemotherapy is shown in Table 4.
There was a slight positive correlation between BCL-2 mRNA
expression   and   the   clinical   response   to   chemotherapy
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Table 3: Comparisons of BCL-2 mRNA expression and ERα mRNA expression with clinical response to neoadjuvant chemotherapy
Responsive Non-responsive
mRNA expression (Mean±SD) (n = 23) (Mean±SD) (n = 7) Mean difference p*
BCL-2 9.887±2.731 10.017±2.122 0.134 0.862
ERα 10.144±1.945 12.433±0.801 2.289 0.006
*p = t-test
Table 4: Correlation of BCL-2 and ERα mRNA expression with the clinical response to neoaduvant chemotherapy
mRNA expression level Correlation with
mRNA (Mean±SD) (n = 30) chemotherapy response (r) p*
BCL-2 11.837±0.360 0.028 0.885
ERα 10.678±1.993 -0.260 0.166
*p = Pearson
(r-value  =  0.028),  but  this  correlation   was   insignificant
(p-value = 0.885, p>0.05). There was a negative correlation
between ERα mRNA expression and the clinical response to
chemotherapy (r-value = -0.260, but this correlation was also
insignificant (p-value = 0.166, p>0.05).
DISCUSSION
This study showed that there were neither significant
differences nor a relationship between BCL-2 mRNA
expression and the clinical response to chemotherapy. The
results suggested that BCL-2 mRNA expression has a minimal
influence on the chemotherapy response.
The BCL-2 protein localizes to the inner mitochondrial
membrane and functions to inhibit apoptosis and promote
survival19,20. The BCL-2 can inhibit apoptosis resulting from a
variety of intracellular signals19,20. The BCL-2 has been shown
into inhibiting apoptosis induced by chemotherapeutic drugs
(including doxorubicin) in cancer cells7.
Abdel fatah et al.9 found that a lack of BCL-2 expression
was associated with high proliferation rates and elevated levels
of P-cadherin, E-cadherin and HER3, while cancers positive
for BCL-2 were correlated with high levels of p27, MDM4 and
SPAG5. The BCL-2 could provide both prognostic and
predictive information to individuals with Triple Negative
Breast Cancer (TNBC)9,22. Patients with TNBC negative for
BCL-2 expression appear to benefit from anthracycline taxane
combination chemotherapy (ATC-CT), whereas patients with
TNBC positive for BCL-2 expression seem to be resistant to
ATC-CT and may benefit from a different type of
chemotherapy9. The elevated BCL-2 expression is a significant
independent predictor of poor outcomes in TNBC patients who
undergo anthracycline-based adjuvant chemotherapy and one
study showed that BCL-2 could predict out comes in TNBC.
Thus,  a  BCL-2  expression  analysis  could  facilitate
decision-making regarding adjuvant treatment in TNBC
patients21.
The BCL-2 expression has been associated with positive
estrogen receptor expression and a favorable prognosis in
breast cancer. Positive expression of BCL-2 predicts no benefit
from adjuvant anthracycline-based chemotherapies patients
with non-basal TNBC. The BCL-2 status showed both
prognostic   and   predictive   values   in   non-basal   TNBCs,
therefore, assessing the BCL-2 status and basal phenotype can
provide information on the prognostic and therapeutic
classifications of TNBCs22.
Other studies found that BCL-2 expression was not
significantly associated with complete pathological response
in patients with triple negative breast cancer and patients in the
BCL-2-negative group tended to be more chemosensitive than
those in the BCL-2-positive group7. This finding is in
agreement with our results showing that BCL-2 could not
predict the response to neoadjuvantchemotherapy.
Dawson et al.8 reviewed five studies comprising 11, 212
women with early-stage breast cancer concluded that BCL-2
is an advantageous independent prognostic indicator for all
types of early-stage breast cancer. Those study sets the
rationale for the introduction of BCL-2 immunohistochemistry
to improve the prognostic stratification of breast cancers8. A
study of 100 samples of breast cancer compared BCL-2 levels
using IHC and RT-PCR techniques and found that measuring
BCL-2 expression in breast cancer using either
immunohistochemistry or RT-PCR produced very similar
results3. These results also suggest an association between
BCL-2 gene expression and favorable biological features and
clinical tumor-small tumor size, low nuclear grade, hormone
receptor expression, the absence of c-erb-B2 and mutant p53
expression and low proliferation rates3. Research on 2749
breast cancer cases concluded that BCL-2 and Ki-67
expression could be combined to produce an index that could
independently predict survival in ER-positive breast cancer,
thus increasing the potential prognostic utility of these
expression markers23. The prognostic role of BCL-2 expression
in breast cancer is subtype-specific. The BCL-2 expression
differs according to the molecular subtype and is only a useful
prognostic marker for luminal A breast cancer24. The
prognostic influence of BCL-2 was also different across
molecular    subtypes    of    breast    cancer    and    was
dependent on HR, HER2 and Ki-67expression as well as
tumor stage25.
This study also showed that there were significant
differences in ERα mRNA expression between the responsive
and nonresponsive groups with p-value = 0.006 (p>0.05).
However, in testing the correlation between ERα mRNA
expression and the clinical response, the results were
insignificant. It can be concluded from this study that ERα
mRNA expression has little influence on the chemotherapeutic
response.
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The estrogen receptor mediates the effects of estrogen on
the development and progression of breast cancer by binding
to specific response elements within a target gene promoter
and activating growth factor pathways via membrane-bound
proteins26. Estrogen E2 predominantly binds to ERα, which
leads to the transcriptional regulation of genes involved in cell
growth and survival. Studies found that ERα knockdown
remarkably  impaired  the  induction  of  BCL-2 and cyclin  D1
as  well  as  survival  via   E227.   The  ERα  is  essential  for
E2-dependent growth and its expression level is a crucial
determinant of the response to endocrine therapy and
prognosis in patients with ERα-positive breast cancer27.
Clinical data suggest that the estrogen receptor contributes to
the chemotherapeutic responsiveness. However, the estrogen
receptor status alone does not consistently predict the
chemotherapeutic response. Chen et al.28 observed TFF1,
ESR1, GATA3 and TFF3 were ER-related genes that were
associated with a complete pathological response (pCR).
Protein expression of ER may provide important predictive
outcomes for responses to neoadjuvant chemotherapy and may
allow for the identification of a subgroup of patients who
could   significantly   benefit   from   chemotherapy28.   The
ER-positive and ER-negative cancers differ in the expression
of specific genes and show distinct patterns of mutations and
alterations in the DNA copy number. Different biological
processes  were  associated  with  the  prognosis  and
chemotherapy response in ER-positive and ER-negative breast
cancers29. Resistance to chemotherapy treatment in breast
cancer  is  multifactorial.  Characterized  mechanisms  of
resistance to chemotherapy treatment are related to the
activities of  estrogen  receptor  α, P-glycoprotein, multidrug
resistance-related proteins and topoisomerase-II. In preclinical
and clinical studies, positive ERα expression in breast cancer
cells  was  correlated  with  decreased  sensitivity  to
chemotherapy30.
Studies found that ERα status may play a significant role
in  determining  the  sensitivity  of  breast  tumors  to
chemotherapy.  Studies  have  shown  that  some
chemotherapeutic agents may beless efficient in patients with
ERα+ tumors than those with ERα- tumors31-33. Other reports
have indicated that ERα is an independent predictive factor for
the pathologic response to neoadjuvant chemotherapy in
primary breast tumors and that ERα negativity is associated
with an improved chemotherapy response34-36. An in vitro
study using ERα-transfected Bcap37 cells and ERα-positive
T47D  breast  cancer  cells  that  were  treated  with
chemotherapeutic agents in the presence or absence of 17-beta
estradiol  (E2)  pretreatment  showed  similar  results.  The
ERα-positive breast cancer cells showed a decreased response
to chemotherapeutic agents due to the influence of ERα on the
growth of breast cancer cells37.
CONCLUSION
This study showed that there was a significant difference
in the ERα mRNA expression levels between responsive and
nonresponsive groups to chemotherapy. However, the
correlation was insignificant. This suggests that ERα mRNA
expression has a reduced influence on the chemotherapy
response. This study showed that there were neither significant
differences nor a correlation between BCL-2 mRNA
expression and the clinical response to neoadjuvant
chemotherapy in breast cancer. This study suggested that
BCL-2 mRNA expression exerts a minimal influence on the
chemotherapy response.
SIGNIFICANCE STATEMENT
This study revealed that BCL-2 mRNA expression
minimally influences the clinical response to neoadjuvant
chemotherapy in patients with breast cancer. High mRNA
expression of ERα tends to associate with a lack of
responsiveness to neoadjuvant chemotherapy in breast cancer,
although the correlation analysis was not significant. The
results of this study suggest a reduced role of BCL-2 and ERα
mRNA in the chemotherapeutic response.
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